{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T21:55:45Z","timestamp":1793051745478,"version":"4.5.0"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2022,1,8]],"date-time":"2022-01-08T00:00:00Z","timestamp":1641600000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,1,8]],"date-time":"2022-01-08T00:00:00Z","timestamp":1641600000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"name":"soonchunhyang university research fund"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Doc Ophthalmol"],"published-print":{"date-parts":[[2022,4]]},"DOI":"10.1007\/s10633-021-09862-8","type":"journal-article","created":{"date-parts":[[2022,1,7]],"date-time":"2022-01-07T19:03:13Z","timestamp":1641582193000},"page":"153-162","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Vogt-Koyanagi-Harada syndrome-like uveitis after nivolumab administration as a treatment for ovarian cancer"],"prefix":"10.1007","volume":"144","author":[{"given":"Gyu Eun","family":"Hwang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jung Woo","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seob","family":"Jeon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"In Hwan","family":"Cho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8353-1656","authenticated-orcid":false,"given":"Hoon Dong","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,1,8]]},"reference":[{"issue":"4","key":"9862_CR1","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1016\/S0039-6257(05)80105-5","volume":"39","author":"RS Moorthy","year":"1995","unstructured":"Moorthy RS, Inomata H, Rao NA (1995) Vogt-Koyanagi-Harada syndrome. Surv Ophthalmol 39(4):265\u2013292","journal-title":"Surv Ophthalmol"},{"issue":"4\u20135","key":"9862_CR2","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1016\/j.autrev.2014.01.023","volume":"13","author":"VM Sakata","year":"2014","unstructured":"Sakata VM et al (2014) Diagnosis and classification of Vogt-Koyanagi-Harada disease. Autoimmun Rev 13(4\u20135):550\u2013555","journal-title":"Autoimmun Rev"},{"issue":"6","key":"9862_CR3","doi-asserted-by":"publisher","first-page":"1063","DOI":"10.1097\/IAE.0000000000002181","volume":"38","author":"LA Dalvin","year":"2018","unstructured":"Dalvin LA et al (2018) Checkpoint inhibitor immune therapy: systemic indications and ophthalmic side effects. Retina 38(6):1063\u20131078","journal-title":"Retina"},{"issue":"19","key":"9862_CR4","doi-asserted-by":"publisher","first-page":"1856","DOI":"10.1056\/NEJMoa1602252","volume":"375","author":"RL Ferris","year":"2016","unstructured":"Ferris RL et al (2016) Nivolumab for recurrent squamous-cell carcinoma of the head and neck. N Engl J Med 375(19):1856\u20131867","journal-title":"N Engl J Med"},{"issue":"19","key":"9862_CR5","doi-asserted-by":"publisher","first-page":"1803","DOI":"10.1056\/NEJMoa1510665","volume":"373","author":"RJ Motzer","year":"2015","unstructured":"Motzer RJ et al (2015) Nivolumab versus everolimus in advanced renal-cell carcinoma. N Engl J Med 373(19):1803\u20131813","journal-title":"N Engl J Med"},{"issue":"4","key":"9862_CR6","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1056\/NEJMoa1412082","volume":"372","author":"C Robert","year":"2015","unstructured":"Robert C et al (2015) Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med 372(4):320\u2013330","journal-title":"N Engl J Med"},{"issue":"12","key":"9862_CR7","doi-asserted-by":"publisher","first-page":"1169","DOI":"10.1080\/14737140.2018.1535315","volume":"18","author":"F Finkelmeier","year":"2018","unstructured":"Finkelmeier F, Waidmann O, Trojan J (2018) Nivolumab for the treatment of hepatocellular carcinoma. Expert Rev Anticancer Ther 18(12):1169\u20131175","journal-title":"Expert Rev Anticancer Ther"},{"key":"9862_CR8","doi-asserted-by":"crossref","unstructured":"Hood DC, et al (2012) ISCEV standard for clinical multifocal electroretinography (mfERG) (2011 edition). Doc Ophthalmol 124(1):1\u201313","DOI":"10.1007\/s10633-011-9296-8"},{"issue":"26","key":"9862_CR9","doi-asserted-by":"publisher","first-page":"2455","DOI":"10.1056\/NEJMoa1200694","volume":"366","author":"JR Brahmer","year":"2012","unstructured":"Brahmer JR et al (2012) Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med 366(26):2455\u20132465","journal-title":"N Engl J Med"},{"issue":"2","key":"9862_CR10","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1172\/JCI96113","volume":"128","author":"H Lin","year":"2018","unstructured":"Lin H et al (2018) Host expression of PD-L1 determines efficacy of PD-L1 pathway blockade-mediated tumor regression. J Clin Invest 128(2):805\u2013815","journal-title":"J Clin Invest"},{"issue":"14","key":"9862_CR11","doi-asserted-by":"publisher","first-page":"1428","DOI":"10.1200\/JCO.2017.76.0793","volume":"36","author":"P Armand","year":"2018","unstructured":"Armand P et al (2018) Nivolumab for relapsed\/refractory classic Hodgkin lymphoma after failure of autologous hematopoietic cell transplantation: extended follow-up of the multicohort single-arm phase II CheckMate 205 trial. J Clin Oncol 36(14):1428\u20131439","journal-title":"J Clin Oncol"},{"issue":"2","key":"9862_CR12","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1016\/j.annonc.2020.10.602","volume":"32","author":"K Khaddour","year":"2021","unstructured":"Khaddour K et al (2021) Mutation clearance and complete radiologic resolution of immunotherapy relapsed metastatic melanoma after treatment with nivolumab and olaparib in a patient with homologous recombinant deficiency: any role for PARP inhibitors and checkpoint blockade? Ann Oncol 32(2):279\u2013280","journal-title":"Ann Oncol"},{"key":"9862_CR13","doi-asserted-by":"crossref","unstructured":"Kudo M (2020) Scientific rationale for combined immunotherapy with PD-1\/PD-L1 antibodies and VEGF inhibitors in advanced hepatocellular carcinoma. Cancers (Basel) 12(5)","DOI":"10.3390\/cancers12051089"},{"issue":"2","key":"9862_CR14","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1016\/S1470-2045(20)30641-0","volume":"22","author":"L Paz-Ares","year":"2021","unstructured":"Paz-Ares L et al (2021) First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in patients with non-small-cell lung cancer (CheckMate 9LA): an international, randomised, open-label, phase 3 trial. Lancet Oncol 22(2):198\u2013211","journal-title":"Lancet Oncol"},{"issue":"16","key":"9862_CR15","doi-asserted-by":"publisher","first-page":"1814","DOI":"10.1200\/JCO.19.02059","volume":"38","author":"D Zamarin","year":"2020","unstructured":"Zamarin D et al (2020) Randomized phase II Trial of nivolumab versus nivolumab and ipilimumab for recurrent or persistent ovarian cancer: an NRG oncology study. J Clin Oncol 38(16):1814\u20131823","journal-title":"J Clin Oncol"},{"key":"9862_CR16","doi-asserted-by":"publisher","first-page":"k4226","DOI":"10.1136\/bmj.k4226","volume":"363","author":"C Xu","year":"2018","unstructured":"Xu C et al (2018) Comparative safety of immune checkpoint inhibitors in cancer: systematic review and network meta-analysis. BMJ 363:k4226","journal-title":"BMJ"},{"issue":"2","key":"9862_CR17","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1080\/00325481.2019.1709344","volume":"132","author":"L Agrawal","year":"2020","unstructured":"Agrawal L et al (2020) Immune checkpoint inhibitors and endocrine side effects, a narrative review. Postgrad Med 132(2):206\u2013214","journal-title":"Postgrad Med"},{"key":"9862_CR18","doi-asserted-by":"crossref","unstructured":"Abdalla Elsayed MEA, Kozak I (2021) Pharmacologically induced uveitis. Surv Ophthalmol","DOI":"10.1016\/j.survophthal.2021.01.003"},{"issue":"2","key":"9862_CR19","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1056\/NEJMoa1302369","volume":"369","author":"JD Wolchok","year":"2013","unstructured":"Wolchok JD et al (2013) Nivolumab plus ipilimumab in advanced melanoma. N Engl J Med 369(2):122\u2013133","journal-title":"N Engl J Med"},{"issue":"5","key":"9862_CR20","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1002\/ccr3.911","volume":"5","author":"T Matsuo","year":"2017","unstructured":"Matsuo T, Yamasaki O (2017) Vogt-Koyanagi-Harada disease-like posterior uveitis in the course of nivolumab (anti-PD-1 antibody), interposed by vemurafenib (BRAF inhibitor), for metastatic cutaneous malignant melanoma. Clin Case Rep 5(5):694\u2013700","journal-title":"Clin Case Rep"},{"issue":"1","key":"9862_CR21","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1186\/s12886-020-01519-5","volume":"20","author":"R Kikuchi","year":"2020","unstructured":"Kikuchi R, Kawagoe T, Hotta K (2020) Vogt-Koyanagi-Harada disease-like uveitis following nivolumab administration treated with steroid pulse therapy: a case report. BMC Ophthalmol 20(1):252","journal-title":"BMC Ophthalmol"},{"issue":"6","key":"9862_CR22","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1111\/1346-8138.14273","volume":"45","author":"T Fujimura","year":"2018","unstructured":"Fujimura T et al (2018) HLA-DRB1*04:05 in two cases of Vogt-Koyanagi-Harada disease-like uveitis developing from an advanced melanoma patient treated by sequential administration of nivolumab and dabrafenib\/trametinib therapy. J Dermatol 45(6):735\u2013737","journal-title":"J Dermatol"},{"issue":"1","key":"9862_CR23","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1159\/000496682","volume":"10","author":"S Obata","year":"2019","unstructured":"Obata S et al (2019) Vogt-Koyanagi-Harada disease-like uveitis during nivolumab (anti-PD-1 antibody) treatment for metastatic cutaneous malignant melanoma. Case Rep Ophthalmol 10(1):67\u201374","journal-title":"Case Rep Ophthalmol"},{"issue":"3","key":"9862_CR24","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1007\/s10633-020-09800-0","volume":"142","author":"H Enomoto","year":"2021","unstructured":"Enomoto H et al (2021) Case with metastatic cutaneous malignant melanoma that developed Vogt-Koyanagi-Harada-like uveitis following pembrolizumab treatment. Doc Ophthalmol 142(3):353\u2013360","journal-title":"Doc Ophthalmol"},{"issue":"5","key":"9862_CR25","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1016\/j.ajo.2008.05.044","volume":"146","author":"P Yang","year":"2008","unstructured":"Yang P et al (2008) Study of macular function by multifocal electroretinography in patients with Vogt-Koyanagi-Harada syndrome. Am J Ophthalmol 146(5):767\u2013771","journal-title":"Am J Ophthalmol"},{"issue":"5","key":"9862_CR26","doi-asserted-by":"publisher","first-page":"e715","DOI":"10.1111\/aos.14646","volume":"99","author":"FMS Souto","year":"2021","unstructured":"Souto FMS et al (2021) Associations between functional and structural measurements in non-acute Vogt-Koyanagi-Harada disease. Acta Ophthalmol 99(5):e715\u2013e723","journal-title":"Acta Ophthalmol"}],"container-title":["Documenta Ophthalmologica"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10633-021-09862-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10633-021-09862-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10633-021-09862-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,4,22]],"date-time":"2022-04-22T12:05:51Z","timestamp":1650629151000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10633-021-09862-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1,8]]},"references-count":26,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2022,4]]}},"alternative-id":["9862"],"URL":"https:\/\/doi.org\/10.1007\/s10633-021-09862-8","relation":{},"ISSN":["0012-4486","1573-2622"],"issn-type":[{"value":"0012-4486","type":"print"},{"value":"1573-2622","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,1,8]]},"assertion":[{"value":"5 July 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 November 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 January 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they have no conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All procedures performed in this case report involving a human participant were in accordance with the ethical standards of Declaration of Helsinki and its later amendments or comparable ethical standards. This report was approved by institutional review board (IRB) of Soonchunhyang University Cheonan Hospital (IRB File No. 2020\u201312-041).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"All procedures performed in this case report involving a human participant were in accordance with the ethical standards of the Soonchunhyang University Cheonan Hospital and with the Declaration of Helsinki and its later amendments.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Statement of human rights"}},{"value":"This report does not contain any studies with animals performed by any of the authors.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Statement on the welfare of animals"}},{"value":"Informed consent was obtained from the participant included in this case report.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}